The lab, which is currently available to customers, can handle highly potent compounds.
CordenPharma announced on Oct. 19, 2020 that it has completed the construction of its highly potent API laboratory in its Boulder, CO facility.
The lab, which is currently available to customers, can handle highly potent compounds with an OEL as low as 1 ng/m3, according to a company press release.
“Our new laboratory in Colorado is part of a development capacity expansion to address the strong market demand. This additional capacity benefits customers by expediting the onboarding of new projects,” said Jason Bertola, director of CordenPharma’s Global Highly Potent & Oncology Platform, in the press release.
Source: CordenPharma
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
PacBio Chosen as Tech Partner for Global Alzheimer’s Disease Research Project
April 23rd 2025The project, the North African Dementia Registry, will unite multiple entities for the purpose of developing a comprehensive dataset to advance the research community’s understanding of Alzheimer’s disease and other dementias in diverse populations.